Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03295227 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
A Phase 1 study of Unresectable Thymic Carcinoma and Stage III Thymoma AJCC v8, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT03295227: Recruiting Phase 1 study of Unresectable Thymic Carcinoma and Stage III Thymoma AJCC v8, sponsored by M.D. Anderson Cancer Center.
NCT03295227 is a Phase 1 study of Unresectable Thymic Carcinoma and Stage III Thymoma AJCC v8 that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 37 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03295227, a Phase 1 study of Unresectable Thymic Carcinoma and Stage III Thymoma AJCC v8, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Primary Outcome
Frequency tables will be used to summarize categorical variables such toxicity type and severity.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-12-06 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT03295227 shows while recruiting
NCT03295227 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% lower).
The record links to 7 conditions, with Unresectable Thymic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03295227 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03295227 about?
NCT03295227 is a clinical study titled "Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer". This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfer...
What is the current status of trial NCT03295227?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2017-12-06. Estimated completion is 2027-12-31.
What conditions does trial NCT03295227 study?
This clinical trial studies the following conditions: Unresectable Thymic Carcinoma, Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8, Stage IIIB Thymoma AJCC v8, Stage IV Thymoma AJCC v8.
What interventions are being tested in trial NCT03295227?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03295227?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03295227 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Thymic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03295227's enrollment target sits among peer trials
37 1204th of 2000 higher than 791 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
- NCT03935984 · 37 participants · Phase 4
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI